Africa’s Diabetes Crisis: Can Generics Companies Step Up?
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
McKinsey’s Johannesburg office opened in 1995, 20 years ago, soon after South Africa’s new democracy brought President Nelson Mandela to power. We have played an active role in the country’s transformation and development—helping top companies win on the world stage, supporting the upgrade of key institutions and infrastructure, building leadership and capabilities. In South Africa and over 40 other countries in Africa, we shape strategy and strengthen operations for players in major industries, and help deliver better outcomes in education and health care. We have over 300 people based in Johannesburg.
Contact
Sandown Mews East
88 Stella Street
Sandown 2196
South Africa
P: 27 (11) 506 8000
F: 27 (11) 506 9561
http://www.mckinsey.com/global_locations/africa/south_africa
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the…
African healthcare and pharma are moving from ambition to action. Regular PharmaBoardroom contributor Lenias Hwenda explains how, after years of over-dependence on global supply chains, fragmented regulation, and limited local…
Africa accounts for 19 percent of the world’s population and one-quarter of the global disease burden. However, for a host of reasons – both real and perceptual – the continent…
Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold,…
Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties…
John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
See our Cookie Privacy Policy Here
